MAP2K7 and esophageal adenocarcinoma: Here, potential additional treatment options for patients with MDM2-amplified esophageal adenocarcinoma could be described, for example, the inhibition of CTL2 or MEK with Trametinib, which is currently under investigation as an antitumoral treatment agent.